Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 695

1.

Good long-term patency: 10-year follow-up using the mid-thigh adductor loop arteriovenous graft.

McEwan SJ, Maple H, Gibbs PJ.

J Vasc Access. 2018 Oct 22:1129729818805955. doi: 10.1177/1129729818805955. [Epub ahead of print]

PMID:
30345875
2.

Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?

Semira C, Wong HL, Field K, Lee M, Lee B, Nott L, Shapiro J, Wong R, Tie J, Tran B, Richardson G, Zimet A, Lipton L, Tamjid B, Burge M, Ma B, Johns J, Harold M, Gibbs P.

Intern Med J. 2018 Sep 19. doi: 10.1111/imj.14115. [Epub ahead of print]

PMID:
30230679
3.

Effect of Aspirin on Disability-free Survival in the Healthy Elderly.

McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, Storey E, Shah RC, Lockery JE, Tonkin AM, Newman AB, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Ryan J, Radziszewska B, Grimm R, Murray AM; ASPREE Investigator Group.

N Engl J Med. 2018 Oct 18;379(16):1499-1508. doi: 10.1056/NEJMoa1800722. Epub 2018 Sep 16.

PMID:
30221596
4.

Effect of Aspirin on All-Cause Mortality in the Healthy Elderly.

McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, Kirpach B, Shah RC, Ives DG, Storey E, Ryan J, Tonkin AM, Newman AB, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Radziszewska B, Grimm R, Murray AM; ASPREE Investigator Group.

N Engl J Med. 2018 Oct 18;379(16):1519-1528. doi: 10.1056/NEJMoa1803955. Epub 2018 Sep 16.

PMID:
30221595
5.

Bridging health access disparities among culturally and linguistically diverse cancer patients: an ongoing challenge.

Semira C, Wong HL, Gibbs P.

Intern Med J. 2018 Sep;48(9):1165. doi: 10.1111/imj.14023. No abstract available.

PMID:
30182388
6.

Accuracy of administrative coding data in colorectal cancer resections and short-term outcomes.

MacCallum C, Da Silva N, Gibbs P, Thomson BNJ, Skandarajah A, Hayes I.

ANZ J Surg. 2018 Sep;88(9):876-881. doi: 10.1111/ans.14714. Epub 2018 Aug 3.

PMID:
30074298
7.

Re. "Why Should Vascular Surgeons be More Involved in Kidney Transplantation?"

Inston N, Gibbs P, Gilbert J.

Eur J Vasc Endovasc Surg. 2018 Sep;56(3):456. doi: 10.1016/j.ejvs.2018.06.068. Epub 2018 Jul 27. No abstract available.

PMID:
30060917
8.

LBA-006Impact of primary tumour location on survival in patients with metastatic colorectal cancer receiving selective internal radiation therapy and chemotherapy as first-line therapy.

van Hazel G, Heinemann V, Sharma N, Taieb J, Ricke J, Peeters M, Findlay M, Gibbs P; SIRFLOX and FOXFIRE-Global trial investigators.

Ann Oncol. 2017 Jun 1;28(suppl_3). doi: 10.1093/annonc/mdx302.005. No abstract available.

PMID:
30052788
9.

Seeding of hepatocellular carcinoma into the stomach wall following endoscopic ultrasound and fine-needle aspiration biopsy.

Kasi M, Rashid S, Wallace SAJ, Sujendran V, Griffiths B, Butler A, Gibbs P, Sreedharan L, Zaitoun AM, Venkatachalapathy S, James MW, Aithal GP.

Oxf Med Case Reports. 2018 Jul 18;2018(7):omy039. doi: 10.1093/omcr/omy039. eCollection 2018 Jul.

10.

Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.

Domingo E, Camps C, Kaisaki PJ, Parsons MJ, Mouradov D, Pentony MM, Makino S, Palmieri M, Ward RL, Hawkins NJ, Gibbs P, Askautrud H, Oukrif D, Wang H, Wood J, Tomlinson E, Bark Y, Kaur K, Johnstone EC, Palles C, Church DN, Novelli M, Danielsen HE, Sherlock J, Kerr D, Kerr R, Sieber O, Taylor JC, Tomlinson I.

Lancet Gastroenterol Hepatol. 2018 Sep;3(9):635-643. doi: 10.1016/S2468-1253(18)30117-1. Epub 2018 Jul 2.

11.

The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern.

Prasanna T, Karapetis CS, Roder D, Tie J, Padbury R, Price T, Wong R, Shapiro J, Nott L, Lee M, Chua YJ, Craft P, Piantadosi C, Sorich M, Gibbs P, Yip D.

Acta Oncol. 2018 Jul 23:1-7. doi: 10.1080/0284186X.2018.1487581. [Epub ahead of print]

PMID:
30035653
12.

Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies.

Gibbs P, Heinemann V, Sharma NK, Taieb J, Ricke J, Peeters M, Findlay M, Robinson B, Jackson C, Strickland A, Gebski V, Van Buskirk M, Zhao H, van Hazel G; SIRFLOX and FOXFIRE Global Trial Investigators.

Clin Colorectal Cancer. 2018 Jun 12. pii: S1533-0028(18)30198-1. doi: 10.1016/j.clcc.2018.06.001. [Epub ahead of print]

PMID:
30033117
13.

Targeted therapy for metastatic colorectal cancer.

Price TJ, Tang M, Gibbs P, Haller DG, Peeters M, Arnold D, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M, Shapiro J.

Expert Rev Anticancer Ther. 2018 Oct;18(10):991-1006. doi: 10.1080/14737140.2018.1502664. Epub 2018 Aug 3.

PMID:
30019590
14.

Mismatch repair deficiency assessment by immunohistochemistry: for Lynch syndrome screening and beyond.

Wong HL, Christie M, Gately L, Tie J, Lee B, Semira C, Lok SW, Wong R, Gibbs P.

Future Oncol. 2018 Nov;14(26):2725-2739. doi: 10.2217/fon-2018-0319. Epub 2018 Jul 13.

PMID:
30004261
15.

Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT.

Selby PJ, Banks RE, Gregory W, Hewison J, Rosenberg W, Altman DG, Deeks JJ, McCabe C, Parkes J, Sturgeon C, Thompson D, Twiddy M, Bestall J, Bedlington J, Hale T, Dinnes J, Jones M, Lewington A, Messenger MP, Napp V, Sitch A, Tanwar S, Vasudev NS, Baxter P, Bell S, Cairns DA, Calder N, Corrigan N, Del Galdo F, Heudtlass P, Hornigold N, Hulme C, Hutchinson M, Lippiatt C, Livingstone T, Longo R, Potton M, Roberts S, Sim S, Trainor S, Welberry Smith M, Neuberger J, Thorburn D, Richardson P, Christie J, Sheerin N, McKane W, Gibbs P, Edwards A, Soomro N, Adeyoju A, Stewart GD, Hrouda D.

Southampton (UK): NIHR Journals Library; 2018 Jun.

16.

Stage-based Variation in the Effect of Primary Tumor Side on All Stages of Colorectal Cancer Recurrence and Survival.

Lee MM, MacKinlay A, Semira C, Schieber C, Jimeno Yepes AJ, Lee B, Wong R, Hettiarachchige CKH, Gunn N, Tie J, Wong HL, Skinner I, Jones IT, Keck J, Kosmider S, Tran B, Field K, Gibbs P.

Clin Colorectal Cancer. 2018 Sep;17(3):e569-e577. doi: 10.1016/j.clcc.2018.05.008. Epub 2018 May 26.

PMID:
29980491
17.

Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry.

Burge M, Semira C, Lee B, Lee M, Kosmider S, Wong R, Shapiro J, Ma B, Dean AP, Zimet AS, Steel SA, Lok SW, Torres J, Eastgate M, Wong HL, Gibbs P.

Clin Colorectal Cancer. 2018 Sep;17(3):e593-e599. doi: 10.1016/j.clcc.2018.05.009. Epub 2018 Jun 1.

PMID:
29958812
18.

Re-inventing the randomized controlled trial in medical oncology: The registry-based trial.

Foroughi S, Wong HL, Gately L, Lee M, Simons K, Tie J, Burgess AW, Gibbs P.

Asia Pac J Clin Oncol. 2018 Jun 26. doi: 10.1111/ajco.12992. [Epub ahead of print] Review.

PMID:
29947051
19.

The Value of Clinical Colorectal Cancer Registries in Colorectal Cancer Research: A Systematic Review.

MacCallum C, Skandarajah A, Gibbs P, Hayes I.

JAMA Surg. 2018 Sep 1;153(9):841-849. doi: 10.1001/jamasurg.2018.1635.

PMID:
29926104
20.

Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer.

Kim TW, Peeters M, Thomas A, Gibbs P, Hool K, Zhang J, Ang AL, Bach BA, Price T.

Clin Cancer Res. 2018 Nov 15;24(22):5602-5609. doi: 10.1158/1078-0432.CCR-17-3377. Epub 2018 Jun 13.

PMID:
29898991
21.

MACROD2 Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors.

Sakthianandeswaren A, Parsons MJ, Mouradov D, MacKinnon RN, Catimel B, Liu S, Palmieri M, Love C, Jorissen RN, Li S, Whitehead L, Putoczki TL, Preaudet A, Tsui C, Nowell CJ, Ward RL, Hawkins NJ, Desai J, Gibbs P, Ernst M, Street I, Buchert M, Sieber OM.

Cancer Discov. 2018 Aug;8(8):988-1005. doi: 10.1158/2159-8290.CD-17-0909. Epub 2018 Jun 7.

PMID:
29880585
22.

Treatment of Sarcoma Lung Metastases with Stereotactic Body Radiotherapy.

Lindsay AD, Haupt EE, Chan CM, Spiguel AR, Scarborough MT, Zlotecki RA, Gibbs PC.

Sarcoma. 2018 Apr 1;2018:9132359. doi: 10.1155/2018/9132359. eCollection 2018.

23.

Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis.

Tang M, Price TJ, Shapiro J, Gibbs P, Haller DG, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M.

Expert Rev Anticancer Ther. 2018 Apr;18(4):339-349. doi: 10.1080/14737140.2018.1444481. Epub 2018 Mar 1.

PMID:
29478352
24.

Outcomes of renal transplant from donors with polycystic kidney disease.

Shamali A, Milsom-Mcquillan S, Gibbs P.

Int J Surg. 2018 Mar;51:229-232. doi: 10.1016/j.ijsu.2018.01.049. Epub 2018 Feb 7. Review.

PMID:
29425828
25.

Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study.

Tie J, Cohen JD, Wang Y, Li L, Christie M, Simons K, Elsaleh H, Kosmider S, Wong R, Yip D, Lee M, Tran B, Rangiah D, Burge M, Goldstein D, Singh M, Skinner I, Faragher I, Croxford M, Bampton C, Haydon A, Jones IT, S Karapetis C, Price T, Schaefer MJ, Ptak J, Dobbyn L, Silliman N, Kinde I, Tomasetti C, Papadopoulos N, Kinzler K, Volgestein B, Gibbs P.

Gut. 2018 Feb 2. pii: gutjnl-2017-315852. doi: 10.1136/gutjnl-2017-315852. [Epub ahead of print]

PMID:
29420226
26.

Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.

Williams DS, Mouradov D, Jorissen RN, Newman MR, Amini E, Nickless DK, Teague JA, Fang CG, Palmieri M, Parsons MJ, Sakthianandeswaren A, Li S, Ward RL, Hawkins NJ, Faragher I, Jones IT, Gibbs P, Sieber OM.

Gut. 2018 Jan 30. pii: gutjnl-2017-315664. doi: 10.1136/gutjnl-2017-315664. [Epub ahead of print]

PMID:
29382774
27.

Detection and localization of surgically resectable cancers with a multi-analyte blood test.

Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, Hruban RH, Wolfgang CL, Goggins MG, Dal Molin M, Wang TL, Roden R, Klein AP, Ptak J, Dobbyn L, Schaefer J, Silliman N, Popoli M, Vogelstein JT, Browne JD, Schoen RE, Brand RE, Tie J, Gibbs P, Wong HL, Mansfield AS, Jen J, Hanash SM, Falconi M, Allen PJ, Zhou S, Bettegowda C, Diaz LA Jr, Tomasetti C, Kinzler KW, Vogelstein B, Lennon AM, Papadopoulos N.

Science. 2018 Feb 23;359(6378):926-930. doi: 10.1126/science.aar3247. Epub 2018 Jan 18.

28.

Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus.

Kennedy A, Brown DB, Feilchenfeldt J, Marshall J, Wasan H, Fakih M, Gibbs P, Knuth A, Sangro B, Soulen MC, Pittari G, Sharma RA.

J Gastrointest Oncol. 2017 Dec;8(6):1079-1099. doi: 10.21037/jgo.2017.09.10. Review.

29.

Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers.

Lee B, Hutchinson R, Wong HL, Tie J, Putoczki T, Tran B, Gibbs P, Christie M.

Semin Cancer Biol. 2018 Oct;52(Pt 2):241-252. doi: 10.1016/j.semcancer.2017.12.009. Epub 2017 Dec 16. Review.

PMID:
29258858
30.

Adequate SIRT activity dose is as important as adequate chemotherapy dose - Authors' reply.

Sharma RA, Gibbs P, Sharma NK, Ricke J, Taieb J, Moschandreas J, Virdee PS, Dutton P, van Hazel G, Wasan HS.

Lancet Oncol. 2017 Nov;18(11):e637. doi: 10.1016/S1470-2045(17)30801-X. Epub 2017 Oct 31. No abstract available.

PMID:
29208391
31.

Aneurysms in vascular access: state of the art and future developments.

Inston N, Mistry H, Gilbert J, Kingsmore D, Raza Z, Tozzi M, Azizzadeh A, Jones R, Deane C, Wilkins J, Davidson I, Ross J, Gibbs P, Huang D, Valenti D.

J Vasc Access. 2017 Nov 17;18(6):464-472. doi: 10.5301/jva.5000828. Epub 2017 Nov 2. Review.

PMID:
29099536
32.

Precision oncology using a clinician-directed, tailored approach to molecular profiling.

Lam M, Tran B, Beck S, Tie J, Herath D, Whittle J, Kwan EM, Fox SB, Fellowes A, Ananda S, Lipton L, Gibbs P, Rosenthal MA, Desai J.

Asia Pac J Clin Oncol. 2018 Feb;14(1):84-90. doi: 10.1111/ajco.12787. Epub 2017 Oct 30.

PMID:
29083093
33.

Circulating tumor DNA as a biomarker to guide therapy in post-operative locally advanced rectal cancer: the best option?

Tie J, Semira C, Gibbs P.

Expert Rev Mol Diagn. 2018 Jan;18(1):1-3. doi: 10.1080/14737159.2018.1386558. Epub 2017 Oct 6. No abstract available.

PMID:
28954554
34.

Understanding barriers and outcomes of unspecified (non-directed altruistic) kidney donation from both professional's and patient's perspectives: research protocol for a national multicentre mixed-methods prospective cohort study.

Gare R, Gogalniceanu P, Maple H, Burnapp L, Clarke A, Williams L, Norton S, Chilcot J, Gibbs P, Mitchell A, McCrone P, Draper H, Mamode N.

BMJ Open. 2017 Sep 21;7(9):e015971. doi: 10.1136/bmjopen-2017-015971.

35.

Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers.

Cohen JD, Javed AA, Thoburn C, Wong F, Tie J, Gibbs P, Schmidt CM, Yip-Schneider MT, Allen PJ, Schattner M, Brand RE, Singhi AD, Petersen GM, Hong SM, Kim SC, Falconi M, Doglioni C, Weiss MJ, Ahuja N, He J, Makary MA, Maitra A, Hanash SM, Dal Molin M, Wang Y, Li L, Ptak J, Dobbyn L, Schaefer J, Silliman N, Popoli M, Goggins MG, Hruban RH, Wolfgang CL, Klein AP, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Lennon AM.

Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10202-10207. doi: 10.1073/pnas.1704961114. Epub 2017 Sep 5.

36.

Molecular signatures of differential responses to exercise trainings during rehabilitation.

Chen YW, Gregory C, Ye F, Harafuji N, Lott D, Lai SH, Mathur S, Scarborough M, Gibbs P, Baligand C, Vandenborne K.

Biomed Genet Genom. 2017;2(1). doi: 10.15761/BGG.1000127. Epub 2017 Apr 10.

37.

Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes.

Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz HJ.

Eur J Cancer. 2017 Oct;84:69-80. doi: 10.1016/j.ejca.2017.07.016. Epub 2017 Aug 5. Review.

38.

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.

Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreas J, Virdee PS, Dutton P, Love S, Gebski V, Gray A; FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-Global trial investigators, van Hazel G, Sharma RA.

Lancet Oncol. 2017 Sep;18(9):1159-1171. doi: 10.1016/S1470-2045(17)30457-6. Epub 2017 Aug 3.

39.

Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies.

Rohr UP, Herrmann P, Ilm K, Zhang H, Lohmann S, Reiser A, Muranyi A, Smith J, Burock S, Osterland M, Leith K, Singh S, Brunhoeber P, Bowermaster R, Tie J, Christie M, Wong HL, Waring P, Shanmugam K, Gibbs P, Stein U.

Ann Oncol. 2017 Aug 1;28(8):1869-1875. doi: 10.1093/annonc/mdx207.

PMID:
28460000
40.

Flaxseed- and Buckwheat-Supplemented Diets Altered Enterobacteriaceae Diversity and Prevalence in the Cecum and Feces of Obese Mice.

Pulkrabek M, Rhee Y, Gibbs P, Hall C.

J Diet Suppl. 2017 Nov 2;14(6):667-678. doi: 10.1080/19390211.2017.1305477. Epub 2017 Apr 13.

PMID:
28406725
41.

Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer.

Virdee PS, Moschandreas J, Gebski V, Love SB, Francis EA, Wasan HS, van Hazel G, Gibbs P, Sharma RA.

JMIR Res Protoc. 2017 Mar 28;6(3):e43. doi: 10.2196/resprot.7201.

42.

Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study.

McNeil JJ, Woods RL, Nelson MR, Murray AM, Reid CM, Kirpach B, Storey E, Shah RC, Wolfe RS, Tonkin AM, Newman AB, Williamson JD, Lockery JE, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Trevaks RE, Orchard SG, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Grimm RH; ASPREE Investigator Group.

J Gerontol A Biol Sci Med Sci. 2017 Oct 12;72(11):1586-1593. doi: 10.1093/gerona/glw342.

43.

Intratumorous heterogeneity for RAS mutations in a treatment-naïve colorectal tumour.

Lunke S, Lee B, Kranz S, Gibbs P, Waring P, Christie M.

J Clin Pathol. 2017 Aug;70(8):720-723. doi: 10.1136/jclinpath-2017-204327. Epub 2017 Mar 17.

PMID:
28314739
44.

How accurate are medical oncologists' impressions of management of metastatic colorectal cancer in Australia?

Au L, Turner N, Wong HL, Field K, Lee B, Boadle D, Cooray P, Karikios D, Kosmider S, Lipton L, Nott L, Parente P, Tie J, Tran B, Wong R, Yip D, Shapiro J, Gibbs P.

Asia Pac J Clin Oncol. 2018 Apr;14(2):e167-e174. doi: 10.1111/ajco.12671. Epub 2017 Mar 16.

PMID:
28299879
45.

Carotenoid glycosides from cyanobacteria are teratogenic in the zebrafish (Danio rerio) embryo model.

Jaja-Chimedza A, Sanchez K, Gantar M, Gibbs P, Schmale M, Berry JP.

Chemosphere. 2017 May;174:478-489. doi: 10.1016/j.chemosphere.2017.01.145. Epub 2017 Jan 31.

46.

Engagement and outcomes for a computerised cognitive-behavioural therapy intervention for anxiety and depression in African Americans.

Jonassaint CR, Gibbs P, Belnap BH, Karp JF, Abebe KK, Rollman BL.

BJPsych Open. 2017 Jan 2;3(1):1-5. doi: 10.1192/bjpo.bp.116.003657. eCollection 2017 Jan.

47.

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).

Pinter T, Klippel Z, Cesas A, Croitoru A, Decaestecker J, Gibbs P, Hotko Y, Jassem J, Kurteva G, Novotny J, O'Reilly S, Salek T, Reiner M, Morrow PK, Choi MR, Whittaker S, Blanke C.

Clin Colorectal Cancer. 2017 Jun;16(2):103-114.e3. doi: 10.1016/j.clcc.2016.08.008. Epub 2016 Sep 7.

PMID:
28038865
48.

The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study.

Lee B, Wong HL, Tacey M, Tie J, Wong R, Lee M, Nott L, Shapiro J, Jennens R, Turner N, Tran B, Ananda S, Yip D, Richardson G, Parente P, Lim L, Stefanou G, Burge M, Iddawela M, Power J, Gibbs P.

Asia Pac J Clin Oncol. 2017 Aug;13(4):314-321. doi: 10.1111/ajco.12639. Epub 2016 Nov 25.

PMID:
27885818
49.

Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal Adenocarcinoma.

Tay RY, Jamnagerwalla M, Steel M, Wong HL, McKendrick JJ, Faragher I, Kosmider S, Hastie I, Desai J, Tacey M, Gibbs P, Wong R.

Clin Colorectal Cancer. 2017 Jun;16(2):e45-e54. doi: 10.1016/j.clcc.2016.09.011. Epub 2016 Oct 6.

PMID:
27825672
50.

Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.

Day D, Kanjanapan Y, Kwan E, Yip D, Lawrentschuk N, Davis ID, Azad AA, Wong S, Rosenthal M, Gibbs P, Tran B.

Intern Med J. 2016 Nov;46(11):1291-1297. doi: 10.1111/imj.13202.

PMID:
27507629

Supplemental Content

Support Center